SCHEMBL7979181

SCHEMBL7979181

CC(C)(C)OC(=O)NCCCCC(N)C(=O)OCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.59
DPP8 Q6V1X1 3/20 0.56
DPP7 Q9UHL4 3/20 0.56
ANPEP P15144 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.53
SYK P43405 1/20 0.53
DPP4 P27487 2/20 0.53
DPP9 Q86TI2 2/20 0.53
POLB P06746 1/20 0.52
MAPK1 P28482 1/20 0.52
KLK7 P49862 2/20 0.51
KLK5 Q9Y337 2/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
RECQL P46063 1/20 0.50
SLC1A3 P43003 1/20 0.49
SLC1A1 P43005 1/20 0.49
IDO1 P14902 1/20 0.49
HTT P42858 1/20 0.48
GAA P10253 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5490556 1.00 MAPT (0.59) MAPTDPP8DPP7ANPEPL3MBTL1
SCHEMBL20168169 1.00 MAPT (0.59) MAPTDPP8DPP7ANPEPL3MBTL1
Hydrochloric Acid SCHEMBL29401553 0.99 MAPT (0.58) MAPTDPP8DPP7ANPEPL3MBTL1
SCHEMBL28198501 0.97 MAPT (0.56) MAPTDPP8DPP7ANPEPL3MBTL1
SCHEMBL28251423 0.97 MAPT (0.56) MAPTDPP8DPP7ANPEPL3MBTL1
SCHEMBL21164376 0.96 MAPT (0.55) MAPTDPP8DPP7ANPEPL3MBTL1
Hydrochloric Acid SCHEMBL29401089 0.95 MAPT (0.54) MAPTDPP8DPP7ANPEPL3MBTL1
SCHEMBL17878734 0.92 SYK (0.56) MAPTDPP8DPP7L3MBTL1SYK
SCHEMBL3824366 0.91 MAPT (0.56) MAPTDPP8DPP7ANPEPL3MBTL1
SCHEMBL7295558 0.91 MAPT (0.56) MAPTDPP8DPP7ANPEPL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4271387-A1 NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCS CONTAINING AND USE THEREOF Immunext, Inc. (US) 2023-11-08 EP disclosed
US-20230310634-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF IMMUNEXT INC (US) 2023-10-05 US disclosed
CN-111484543-B Lipopeptide TLR2 agonist and medicinal composition and application thereof 复旦大学 2023-03-28 CN disclosed
EP-4136118-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF Immunext, Inc. (US) 2023-02-22 EP disclosed
EP-3541381-B1 INHIBITORS OF FACTOR XIIA MERCK SHARP & DOHME LLC (US) 2022-12-28 EP disclosed
WO-2022150637-A1 NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF IMMUNEXT, INC. (US) 2022-07-14 WO disclosed
EP-3222617-B1 PSMA-TARGETING COMPOUNDS AND USES THEREOF UNIV JOHNS HOPKINS (US) 2022-07-06 EP disclosed
WO-2021216913-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF IMMUNEXT, INC. (US) 2021-10-28 WO disclosed
US-11014920-B2 Factor XIIa inhibitors MERCK SHARP & DOHME CORP. (US) 2021-05-25 US disclosed
US-20200262831-A1 Factor XIIa Inhibitors MERCK SHARP & DOHME CORP. (US) 2020-08-20 US disclosed
CN-111484543-A Lipopeptide T L R2 agonist and medicinal composition and application thereof 复旦大学 2020-08-04 CN disclosed
EP-3541381-A1 FACTOR XIIa INHIBITORS Merck Sharp & Dohme Corp. (US) 2019-09-25 EP disclosed
WO-2018093716-A1 FACTOR XIIa INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-05-24 WO disclosed
US-9776977-B2 PSMA-targeting compounds and uses thereof THE JOHNS HOPKINS UNIVERSITY (US) 2017-10-03 US disclosed
EP-3222617-A1 PSMA-TARGETING COMPOUNDS AND USES THEREOF The Johns Hopkins University (US) 2017-09-27 EP disclosed
EP-2408755-B1 Urea-based peptide compounds useful for detecting inter alia prostate cancer UNIV JOHNS HOPKINS (US) 2017-05-03 EP disclosed
US-20150104387-A1 PSMA-TARGETING COMPOUNDS AND USES THEREOF THE JOHNS HOPKINS UNIVERSITY (US) 2015-04-16 US disclosed
WO-2001002370-A9 NICKEL-BASED REAGENTS FOR DETECTING DNA AND DNA-PROTEIN CONTACTS UNIV MARYLAND (US) 2001-07-12 WO disclosed
WO-2001002370-A1 NICKEL-BASED REAGENTS FOR DETECTING DNA AND DNA-PROTEIN CONTACTS UNIVERSITY OF MARYLAND, COLLEGE PARK (US) 2001-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11014920-B2 Factor XIIa inhibitors F11, F13B, SERPINC1 MAPT 4426/4885DPP8 2161/4885DPP7 927/4885
US-20150104387-A1 PSMA-TARGETING COMPOUNDS AND USES THEREOF FOLH1, KLK3, PSMA2 MAPT 973/4885DPP8 148/4885DPP7 140/4885
US-20200262831-A1 Factor XIIa Inhibitors F11, F13B, SERPINC1 MAPT 4426/4885DPP8 2161/4885DPP7 927/4885
US-20230310634-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF CD47, CLTA, FCGR2A MAPT 199/4885DPP8 2730/4885DPP7 3065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.